An infant with Kasabach-Merritt syndrome was treated with interferon-alfa 2b. Clinical and hematological responses were followed. Intron-A (Schering-Plough) was administered to a two and half-month-old male infant after failure of most other conventional therapies. A daily dose of 100,000 u/Kg was given subcutaneously for a total of 122 days. Clinical and laboratory aggravation was observed in the first eight days. The fibrinogen level increased to > 100 mg/dl after two weeks of Intron-A treatment. Local inflammatory signs began to improve after 21 days. The platelet count became normal after 80 days of treatment. During follow-up, there was continuous regression of the tumor.